Related Experiment Videos
Cor pulmonale in cystic fibrosis
Michael Eckles1, Paula Anderson
1Division of Pulmonary and Critical Care Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA.
Seminars in Respiratory and Critical Care Medicine
|August 10, 2005
Summary
Cystic fibrosis (CF) management focuses on treating cor pulmonale by correcting hypoxemia and reducing pulmonary artery pressures. Key therapies include oxygen, antibiotics, airway clearance, and potentially lung transplantation for advanced disease.
Area of Science:
- Pulmonology
- Genetics
- Cardiology
Background:
- Cystic fibrosis (CF) is an autosomal recessive disorder caused by a defective chloride channel.
- Genetic discoveries have improved understanding and treatment of CF pathophysiology.
- Chronic lung infections, pancreatic insufficiency, and high sweat chloride are characteristic of CF.
Purpose of the Study:
- To outline the therapeutic goals for cor pulmonale in cystic fibrosis patients.
- To emphasize the importance of managing hypoxemia and pulmonary hypertension.
- To review current and potential treatment options for advanced CF lung disease.
Main Methods:
- Review of current therapeutic strategies for cor pulmonale in CF.
- Assessment of oxygenation during sleep and exercise.
- Evaluation of lung transplantation as a treatment for end-stage disease.
Main Results:
- Cor pulmonale develops secondary to progressive lung disease in CF.
- Pulmonary hypertension correlates with hypoxemia and mortality.
- Effective management involves supplemental oxygen and aggressive pulmonary treatment.
Conclusions:
- Therapy for cor pulmonale in CF aims to improve oxygenation and lower pulmonary artery pressure.
- Aggressive pulmonary disease management and oxygen therapy are crucial.
- Lung transplantation is a viable option for end-stage CF with cor pulmonale.